Alphatec (NASDAQ:ATEC) Issues Quarterly Earnings Results

Key Points

• Alphatec reported a quarterly earnings of $0.02 per share, exceeding analyst expectations of ($0.06), with revenues of $185.54 million, higher than the forecast of $178.85 million.
• The company's stock traded up to $13.77 following the earnings report, with a substantial trading volume of 12,995,953 shares.
• Alphatec's price targets have been revised upward by several analysts, with a consensus price target of $18.33 and multiple firms maintaining a "buy" rating.

Alphatec (NASDAQ:ATEC - Get Free Report) announced its quarterly earnings data on Thursday. The medical technology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.08, Briefing.com reports. The firm had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The company's quarterly revenue was up 27.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.29) EPS. Alphatec updated its FY 2025 guidance to EPS.

Alphatec Stock Performance

Shares of ATEC stock traded up $3.19 on Friday, hitting $13.77. The company had a trading volume of 12,995,953 shares, compared to its average volume of 1,435,736. The firm has a market cap of $2.01 billion, a P/E ratio of -12.19 and a beta of 1.05. The stock's 50-day moving average is $11.37 and its two-hundred day moving average is $11.16. Alphatec has a twelve month low of $4.88 and a twelve month high of $13.89.

Insider Activity

In other news, EVP Craig E. Hunsaker sold 13,878 shares of the stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $12.36, for a total value of $171,532.08. Following the completion of the sale, the executive vice president owned 1,450,018 shares of the company's stock, valued at approximately $17,922,222.48. This represents a 0.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Karen K. Mcginnis sold 3,963 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $12.11, for a total value of $47,991.93. Following the sale, the director owned 68,709 shares in the company, valued at approximately $832,065.99. The trade was a 5.45% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 299,547 shares of company stock valued at $3,698,956. Company insiders own 20.90% of the company's stock.

Institutional Investors Weigh In On Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Dynamic Technology Lab Private Ltd bought a new position in Alphatec in the first quarter worth approximately $257,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Alphatec by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company's stock worth $750,000 after acquiring an additional 3,196 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Alphatec by 18.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company's stock worth $2,696,000 after acquiring an additional 41,264 shares in the last quarter. Institutional investors own 66.35% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective for the company in a report on Monday, June 16th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price target on shares of Alphatec in a report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Friday. Finally, Piper Sandler reissued an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.33.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.